Skip to Content
Global News Select

Zoetis 1Q Beats Analyst Views

By Michael Dabaie


Zoetis Inc. reported first-quarter earnings and revenue above analyst expectations.

The animal health company reported first-quarter revenue of $1.87 billion, up from $1.53 billion in the year ago period and above the FactSet consensus forecast of analysts for $1.72 billion.

Net income attributable to Zoetis was $559 million, up from $423 million a year earlier.

Earnings per share were $1.17 for the quarter, up from 88 cents.

The company reported adjusted EPS of $1.26, beating the FactSet consensus for $1.04.

Revenue in the U.S. segment was $933 million, up 19% on year. Sales of companion animal products increased 32%, driven by growth in its parasiticides portfolio, the company said.

Revenue in the international segment was $922 million, up 27% on a reported basis.

Zoetis boosted its 2021 revenue forecast to between $7.5 billion and $7.63 billion. In February the company guided for 2021 revenue of between $7.4 billion and $7.55 billion.

Zoetis forecast full-year earnings per share of $4.08 to $4.19, versus earlier guidance of $4.02 to $4.14.

The company's new guidance for adjusted EPS is $4.42 to $4.51, up from February's forecast of $4.36 to $4.46.

"Looking ahead, we are raising guidance for operational growth in full-year revenue to the range of 10.5% to 12%. The fundamental growth drivers for our industry continue to show strong and sustainable momentum, and we remain confident that our diverse portfolio across species and geographies, our pipeline of innovative new products and lifecycle innovations, and the agility and commitment of our colleagues will continue driving our success in 2021 and beyond," Chief Executive Kristin Peck said.


Write to Michael Dabaie at


(END) Dow Jones Newswires

May 06, 2021 09:05 ET (13:05 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.